Benefits of preserving residual renal function in peritoneal dialysis

Kidney International

Volumn 73, Issue SUPPL. 108, 2008, Pages

  Marron B ^a,e   Remon C ^b   Perez Fontan M ^c   Quiros P ^b   Ortiz A ^d  

^a Renal Division Baxter   (Spain)

^b HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^e Medical Affairs   (Spain)

Author keywords

Benefits; Hemodialysis; Peritoneal dialysis; Preservation; Residual renal function

Indexed keywords

AMINO ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA 2 MICROGLOBULIN; BICARBONATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; ICODEXTRIN; PHOSPHATE; RAMIPRIL; SODIUM; URIC ACID; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG EFFECT; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; NUTRITIONAL ASSESSMENT; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; CHRONIC KIDNEY FAILURE; KIDNEY; METHODOLOGY; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY;

CARDIOVASCULAR DISEASES; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; NUTRITIONAL STATUS; PERITONEAL DIALYSIS; PERITONITIS; RENAL DIALYSIS;

EID: 44449177272     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002600     Document Type: Article

References (100)

1. Ahmad S, Babb AL, Milutinovic J et al. Effect of residual renal function on minimum dialysis requirements. Proc Eur Dial Transplant Assoc 1979; 16: 107-114.
2. Suda T, Hiroshige K, Ohta T et al. The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant 2000; 15: 396-401.
3. Rottembourg J, Issad B, Gallego JL et al. Evolution of residual renal function in patients undergoing maintenance haemodialysis or continuous ambulatory peritoneal dialysis. Proc EDTA 1983; 19: 397-403.
4. Lysaght MJ, Vonesh EF, Gotch F et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37: 598-604.
5. Moist LM, Port FK, Orzol SM et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11: 556-564.
6. Misra M, Vonesh E, Van Stone JC et al. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int 2001; 59: 754-763.
7. Lang SM, Bergner A, Topfer M et al. Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors. Perit Dial Int 2001; 21: 52-57.
8. Jansen MA, Hart AA, Korevaar JC et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62: 1046-1053.
9. Cancarini GC, Brunori G, Camerini C et al. Renal function recovery and maintenance of residual diuresis in CAPD and hemodialysis. Perit Dial Bull 1986; 6: 77-79.
10. Chandna SM, Farrington K. Residual renal function: considerations on its importance and preservation in dialysis patients. Semin Dial 2004; 17: 196-201.
11. Diaz-Buxo JA, Lowrie EG, Lew NL et al. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis 1999; 33: 523-534.
12. Rocco M, Soucie JM, Pastan S, McClellan WM. Peritoneal dialysis adequacy and risk of death. Kidney Int 2000; 58: 446-457.
13. Shemin D, Bostom AG, Laliberty P et al. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38: 85-90.
14. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162.
15. Rocco MV, Frankenfield DL, Prowant B et al. Risk factors for early mortality in US peritoneal dialysis patients: impact of residual renal function. Perit Dial Int 2002; 22: 371-379.
16. Termorshuizen F, Korevaar JC, Dekker FW et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003; 41: 1293-1302.
17. Wang AY, Woo J, Wang M et al. Important differentiation of factors that predict outcome in peritoneal dialysis patients with different degrees of residual renal function. Nephrol Dial Transplant 2005; 20: 396-403.
18. Menon MK, Naimark DM, Bargman JM et al. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001; 16: 2207-2213.
19. Wang AY, Wang M, Woo J et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002; 62: 639-647.
20. Wang AY, Wang M, Woo J et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15: 2186-2194.
21. Morduchowicz G, Winkler J, Zabludowski JR et al. Effects of residual renal function in haemodialysis patients. Int Urol Nephrol 1994; 26: 125-131.
22. Ates K, Nergizoglu G, Keven K et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60: 767-776.
23. Konings CJAM, Kooman JP, Schonck M et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant 2003; 18: 797-803.
24. Mistry CD, O'Donoghue DJ, Nelson S et al. Kinetic and clinical studies of beta 2-microglobulin in continuous ambulatory peritoneal dialysis: influence of renal and enhanced peritoneal clearances using glucose polymer. Nephrol Dial Transplant 1990; 5: 513-519.
25. Montenegro J, Martinez I, Saracho R, Gonzalez R. Beta 2 microglobulin in CAPD. Adv Perit Dial 1992; 8: 369-372.
26. Suda T, Hiroshige K, Ohta T et al. The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol Dial Transplant 2000; 15: 396-401.
27. Bammens B, Evenepoel P, Verbeke K et al. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am J Kidney Dis 2005; 46: 512-519.
28. Szeto CC, Lai KN, Wong TY et al. Independent effects of residual renal function and dialysis adequacy on nutritional status and patient outcome in continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1999; 34: 1056-1064.
29. Wang AY, Sea MM, Ip R et al. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2001; 12: 2450-2457.
30. Pecoits-Filho R, Heimburger O, Barany P et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41: 1212-1218.
31. Gao H, Lew SQ, Ronco C et al. The impact of residual renal function and total body water volume on achieving adequate dialysis in CAPD. J Nephrol 1999; 12: 184-189.
32. Page DE, Knoll GA, Cheung V. The relationship between residual renal function, protein catabolic rate, and phosphate and magnesium levels in peritoneal dialysis patients. Adv Perit Dial 2002; 18: 189-191.
33. Kagan A, Elimalech E, Lemer Z et al. Residual renal function affects lipid profile in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1997; 17: 243-249.
34. Pérez-Fontán M, Rodríguez-Carmona A, García Naveiro R et al. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int 2005; 25: 274-284.
35. Han SH, Lee SC, Ahn SV et al. Reduced residual renal function is a risk factor for peritonitis in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 2007; 22: 2653-2658.
36. Liu YL, Huang CC, Kao MT. Residual renal function predicts outcome of fungal peritonitis in peritoneal dialysis patients. Perit Dial Int 2006; 26: 407-409.
37. Maiorca R, Brunori G, Zubani R et al. Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients: A longitudinal study. Nephrol Dial Transplant 1995; 10: 2295-2305.
38. Churchill DN, Taylor DW, Keshaviah PR. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. J Am Soc Nephrol 1996; 7: 198-207.
39. Szeto CC, Wong TYH, Leung CB et al. Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int 2000; 58: 400-407.
40. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320.
41. Chung SH, Heimburger O, Stenvinkel P et al. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 2003; 18: 590-597.
42. Szeto CC, Wong TYH, Chow KM et al. Are peritoneal dialysis patients with and without residual renal function equivalent for survival study? Insight from a retrospective review of the cause of death. Nephrol Dial Transplant 2003; 18: 977-982.
43. Foley RN, Parfrey PS, Sarnak MJ. The clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(Suppl 3): S112-S119.
44. Davies SJ, Brown EA, Frandsen NE et al. Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67: 1609-1615.
45. Menon MK, Naimark DM, Bargman JM et al. Long term blood pressure control in a cohort of peritoneal dialysis patients and its associations with residual renal function. Nephrol Dial Transplant 2001; 16: 2207-2213.
46. Buckalew Jr VM, Berg RL, Wang SR et al. Prevalence of hypertension on 1975 subjects with chronic renal disease: the modification of diet in renal disease study: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996; 28: 811-821.
47. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
48. Silberberg JS, Barre PE, Prichard SS et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-290.
49. Silberberg JS, Rahal DP, Patton R et al. Role of anemia in the pathogenesis of left ventricular hypertrophy in endstage renal disease. Am J Cardiol 1989; 64: 222-224.
50. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.
51. Vlahakos DV, Hahalis G, Vassilakos P et al. Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol 1997; 8: 1764-1770.
52. Converse RL, Jacobsen TN, Toto R et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918.
53. Aguilera A, Codoceo R, Selgas R et al. Anorexigen (TNF-α, cholecystokinin) and orexigen (Neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. Nephrol Dial Transplant 1998; 13: 1476-1483.
54. Plata-Salamán C. Cytokines and feeding suppression: an integrative view from neurologic to molecular levels. Nutrition 1995; 11: S674-S677.
55. Amore A, Coppo R. Immunological basis of inflammation in dialysis. Nephrol Dial Transplant 2002; 17: S16-S24.
56. Aguilera A, Velásquez E, Bajo MA et al. Systemic inflammation induces endothelial dysfunction in peritoneal dialysis patients. Vasc Dis Prevent 2007 (in press).
57. Wang AY, Sea MM, Tang N et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol 2004; 15: 3134-3143.
58. Shin SK, Noh H, Kang SW et al. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19: 138-142.
59. Johnson DW, Mudge DW, Sturtevant JM et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int 2003; 23: 276-283.
60. Fischbach M, Terzic J, Menouer S et al. Effects of automated peritoneal dialysis on residual daily urinary volume in children. Adv Perit Dial 2001; 17: 269-273.
61. McKane W, Chandna SM, Tattersall JE et al. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int 2002; 61: 256-265.
62. Van Stone JC. The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO J 1995; 41: M713-M716.
63. Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997; 30: 366-373.
64. Caramelo C, Alcazar R, Gallar P et al. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol Dial Transplant 1994; 9: 675-677.
65. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17: 1814-1818.
66. McIntyre CW. Bimodal dialysis: an integrated approach to renal replacement therapy. Perit Dial Int 2004; 24: 547-553.
67. Lameire NH. The impact of residual renal function on the adequacy of peritoneal dialysis. Nephron 1997; 77: 13-28.
68. Rottembourg J, Issad B, Allouache M et al. Recovery of renal function in patients treated by CAPD. Adv Perit Dial 1989; 5: 63-66.
69. Katz IJ, Sofianou L, Butler O et al. Recovery of renal function in Black South African patients with malignant hypertension: superiority of continuous ambulatory peritoneal dialysis over hemodialysis. Perit Dial Int 2001; 21: 581-586.
70. Wang T, Ye RG, Zhen ZH et al. Influence of peritoneal dialysis on the progression of chronic renal failure. Adv Perit Dial 1995; 11: 139-141.
71. Berlanga JR, Marron B, Reyero A et al. Peritoneal dialysis retardation of progression of advanced renal failure. Perit Dial Int 2002; 22: 239-242.
72. Van Biesen W, Dequidt C, Vanholder R et al. The impact of healthy start peritoneal dialysis on the evolution of residual renal function and nutrition parameters. Adv Perit Dial 2002; 18: 44-48.
73. Coronel F, Pérez-Flores I, Calvo N et al. Impact of cardiovascular events on residual renal function during the first year of peritoneal dialysis. Perit Dial Int 2007; 27: 454-456.
74. Hidaka H, Nakao T. Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis. Nephrology 2003; 8: 184-191.
75. Foggensteiner L, Baylis J, Moss H et al. Timely initiation of dialysis - single-exchange experience in 39 patients starting peritoneal dialysis. Perit Dial Int 2002; 22: 471-476.
76. Burkart JM, Satko SG. Incremental initiation of dialysis: one center's experience over a two-year period. Perit Dial Int 2000; 20: 418-422.
77. Hiroshige K, Yuu K, Soejima M et al. Rapid decline of residual renal function in patients on automated peritoneal dialysis. Perit Dial Int 1996; 16: 307-315.
78. Hufnagel G, Michel C, Queffeulou G et al. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 1999; 14: 1224-1228.
79. Rodriguez-Carmona A, Pérez-Fontán M, Garca-Naveiro R et al. Compared time profiles of ultrafiltration, sodium removal, and renal function in incident CAPD and automated peritoneal dialysis patients. Am J Kidney Dis 2004; 44: 132-145.
80. Selby NM, Fonseca S, Hulme L et al. Automated peritoneal dialysis has significant effects on systemic hemodynamics. Perit Dial Int 2006; 26: 328-335.
81. de Fijter CW, ter Wee PM, Donker AJM. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 2000; 15: 1094-1096.
82. Bro S, Bjorner JB, Tofte-Jensen P et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int 1999; 19: 526-533.
83. Rodriguez AM, Diaz NV, Cubillo LP et al. Automated peritoneal dialysis: a Spanish multicentre study. Nephrol Dial Transplant 1998; 13: 2335-2340.
84. Holley JL, Aslam N, Bernardini J et al. The influence of demographic factors and modality on loss of residual renal function in incident peritoneal dialysis patients. Perit Dial Int 2001; 21: 302-305.
85. Singhal MK, Bhaskaran S, Vidgen E et al. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 2000; 20: 429-438.
86. Gallar P, Ortega O, Carreno A et al. Rate of decline in residual renal function is equal in CAPD and automated peritoneal dialysis patients. Perit Dial Int 2000; 20: 803-805.
87. Nussbaum SR. Pathophysiology and management of severe hypercalcemia. Endocrinol Metab Clin N Am 1993; 22: 343-362.
88. Faller B, Lameire N. Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years. Nephrol Dial Transplant 1994; 9: 280-286.
89. Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001; 59: 1128-1133.
90. Li PK, Chow KM, Wong TY et al. Effects of an angiotensin- converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139: 105-112.
91. Suzuki H, Kanno Y, Sugahara S et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43: 1056-1064.
92. Davies SJ, Woodrow G, Donovan K et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344.
93. Adachi Y, Nakagawa Y, Nishio A. Icodextrin preserves residual renal function in patients treated with automated peritoneal dialysis. Perit Dial Int 2006; 26: 405-407.
94. Ho-Dac-Pannekeet MM, Schouten N, Langendijk MJ et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996; 50: 979-986.
95. Konings CJ, Kooman JP, Gladziwa U et al. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int 2005; 67: 1190-1191.
96. Lo WK. Effect of PD solutions on patient outcome. Contrib Nephrol 2006; 150: 90-96.
97. le Poole CY, Van Ittersum FJ, Weijmer MC et al. Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. Adv Perit Dial 2004; 20: 170-176.
98. Taylor GS, Patel V, Spencer S et al. Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients. Clin Nephrol 2002; 58: 445-450.
99. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418.
100. Montenegro J, Saracho RM, Martinez IM et al. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26: 89-94.